<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sixty-seven evaluable patients with mixed cellular and histiocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, both nodular and diffuse, were treated with a combined drug regimen of BCNU, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> administered for six monthly courses </plain></SENT>
<SENT sid="1" pm="."><plain>Of 28 previously untreated patients with diffuse histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 14 (50%) achieved a complete remission, and an additional 7 (25%) had a good partial response for an overall remission rate of 75% </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remissions were also obtained among the small number of mixed and nodular histiocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> which were treated </plain></SENT>
<SENT sid="3" pm="."><plain>The median survival for previously untreated patients with diffuse histiocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who achieved a complete remission is nearly two years and 42% (8/19) of these patients remain in their initial unmaintained remission (range 2-119 weeks) </plain></SENT>
<SENT sid="4" pm="."><plain>Hematologic toxicity, although acceptable, was the limiting factor </plain></SENT>
<SENT sid="5" pm="."><plain>Granulocytes were more often and more severely depressed than platelets </plain></SENT>
</text></document>